Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Researchers identify role of gene in schizophrenia
The finding adds to mounting evidence of dopamine’s link to psychiatric and neurological disorders. It may also allow physicians to pinpoint a subset of these children for treatment
The finding adds to mounting evidence of dopamine’s link to psychiatric and neurological disorders. It may also allow physicians to pinpoint a subset of these children for treatment
The experiment was carried out in a fluid percussion injury model, a widely accepted rat model that simulates moderate head injury with prolonged cognitive deficits sustained in humans.
According to the company, the findings demonstrate the potential of adipose stem cells in the treatment of cardiovascular disease, including heart attacks, congestive heart failure and peripheral vascular
Researchers at the University of Pennsylvania School of Medicine and the University of Maryland are reporting the successful results of their clinical trial of “immunotherapy” in this week’s
In the collaboration, Boehringer peptides will be developed for inhalation using Syntonix’ SynFusion drugs and Transceptor technology. Under the terms of the agreement, Syntonix will receive an upfront
In the experiments, eight Neugene antisense compounds were developed to target regions of the influenza virus genome believed to be critical to virus survival. AVI also selected regions
The approvable letter represents a delay in the drug’s path to market, as it asks for the company to submit more data before it can be approved. However,
The product, 2-methoxyestradiol (2ME2), is currently in clinical trials for cancer and in preclinical development for rheumatoid arthritis. The company also recently gained a US patent covering compositions
Sigma-Aldrich will commercialize the technology for the reagent and research tool market, becoming Oxford BioMedica’s exclusive global partner in the development and marketing of research products based on
The trial is being initiated as a result of a patient recruitment delay faced by Novel 3, one of two ongoing phase III studies of sargramostim in Crohn’s